beta-TrCP1-variant 4, a novel splice variant of beta-TrCP1, is a negative regulator of beta-TrCP1-variant 1 in beta-catenin degradation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Eun-Ju | - |
dc.contributor.author | Cho, Minji | - |
dc.contributor.author | Rho, Seung Bae | - |
dc.contributor.author | Park, Junsoo | - |
dc.contributor.author | Chae, Dhan-Ah | - |
dc.contributor.author | Nguyen, Que Thanh Thanh | - |
dc.date.accessioned | 2021-08-12T02:40:16Z | - |
dc.date.available | 2021-08-12T02:40:16Z | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 0006-291X | - |
dc.identifier.issn | 1090-2104 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/48086 | - |
dc.description.abstract | beta-transducin repeats-containing protein-1 (beta-TrCP1) serves as the substrate recognition subunit for SCF beta-TrCP E3 ubiquitin ligases, which specifically ubiquitinate phosphorylated substrates. Three variants of beta-TrCP1 are known and act as homodimer or heterodimer complexes. Here, we identified a novel full-sequenced variant, beta-TrCP1-variant 4, which harbours exon II instead of exon III of variant 1, with no change in the open reading frame. The expression of beta-TrCP1-variant 4 is lower than that of variant 1 or 2 in ovarian cancer cell lines, whereas it is abundantly expressed in normal and cancerous ovarian tissues. Moreover, beta-TrCP1-variant 2 was aberrantly expressed more than variant 1 in ovarian cancer tissues whereas variant 1 was expressed more in normal tissues. Similar to variants 1 and 2, beta-TrCP1-variant 4 directly interacts with beta-catenin, one of the substrates of SCF beta-TrCP E3 ubiquitin ligase and downregulates the transcriptional activity and protein expression of beta-catenin with a significantly weaker effect than that by variants 1 and 2. However, the co-expression of beta-TrCP1-variant 4 with variant 1 in same proportion has no effect, whereas other combinations effectively down-regulate the activity of beta-catenin, indicating that the heterodimer of variants 1 and 4 has no function. Thus, beta-TrCP1-variant 4 could play a critical role in SCF beta-TrCP E3 ligase-mediated ubiquitination by acting as a negative regulator of beta-TrCP1-variant 1. (C) 2021 Elsevier Inc. All rights reserved. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | - |
dc.title | beta-TrCP1-variant 4, a novel splice variant of beta-TrCP1, is a negative regulator of beta-TrCP1-variant 1 in beta-catenin degradation | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.bbrc.2021.01.007 | - |
dc.identifier.bibliographicCitation | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, v.542, pp 9 - 16 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000615714300002 | - |
dc.identifier.scopusid | 2-s2.0-85100205472 | - |
dc.citation.endPage | 16 | - |
dc.citation.startPage | 9 | - |
dc.citation.title | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | - |
dc.citation.volume | 542 | - |
dc.type.docType | Article; Early Access | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | beta-TrCP1 | - |
dc.subject.keywordAuthor | Splicing variant | - |
dc.subject.keywordAuthor | beta-catenin | - |
dc.subject.keywordAuthor | SCF beta-TrCP E3 ubiquitin ligases | - |
dc.subject.keywordAuthor | Ovarian cancer | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biophysics | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biophysics | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.